157 related articles for article (PubMed ID: 32965044)
1. A new diagnostic indication device of a biomarker growth differentiation factor 15 for mitochondrial diseases: From laboratory to automated inspection.
Koga Y; Povalko N; Inoue E; Ishii A; Fujii K; Fujii T; Murayama K; Mogami Y; Hata I; Ikawa M; Fukami K; Fukumoto Y; Nomura M; Ichikawa K; Yoshida K
J Inherit Metab Dis; 2021 Mar; 44(2):358-366. PubMed ID: 32965044
[TBL] [Abstract][Full Text] [Related]
2. Comparison of performance characteristics between high-performance liquid chromatography and latex agglutination turbidimetric immunoassay for therapeutic drug monitoring of zonisamide.
Eto D; Tanaka R; Suzuki Y; Sato Y; Itoh H
J Clin Lab Anal; 2019 Sep; 33(7):e22940. PubMed ID: 31218755
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease.
Kamijo-Ikemori A; Sugaya T; Yoshida M; Hoshino S; Akatsu S; Yamazaki S; Kimura K; Shibagaki Y
Clin Chem Lab Med; 2016 Oct; 54(10):1645-54. PubMed ID: 26943609
[TBL] [Abstract][Full Text] [Related]
4. FGF21 outperforms GDF15 as a diagnostic biomarker of mitochondrial disease in children.
Riley LG; Nafisinia M; Menezes MJ; Nambiar R; Williams A; Barnes EH; Selvanathan A; Lichkus K; Bratkovic D; Yaplito-Lee J; Bhattacharya K; Ellaway C; Kava M; Balasubramaniam S; Christodoulou J
Mol Genet Metab; 2022 Jan; 135(1):63-71. PubMed ID: 34991945
[TBL] [Abstract][Full Text] [Related]
5. A sensitive three monoclonal antibodies based automatic latex particle-enhanced turbidimetric immunoassay for Golgi protein 73 detection.
Xia Y; Shen H; Zhu Y; Xu H; Li Z; Si J
Sci Rep; 2017 Jan; 7():40090. PubMed ID: 28054632
[TBL] [Abstract][Full Text] [Related]
6. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders.
Yatsuga S; Fujita Y; Ishii A; Fukumoto Y; Arahata H; Kakuma T; Kojima T; Ito M; Tanaka M; Saiki R; Koga Y
Ann Neurol; 2015 Nov; 78(5):814-23. PubMed ID: 26463265
[TBL] [Abstract][Full Text] [Related]
7. Comparison of electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients.
Akamine Y; Sato S; Kagaya H; Ohkubo T; Satoh S; Miura M
J Clin Pharm Ther; 2018 Oct; 43(5):675-681. PubMed ID: 29679392
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of cyclic citrullinated peptide-immobilized latex beads for measurement of anti-citrillinated protein antibody through latex particle-enhanced turbidimetric immunoassay.
Deng X; Zeng M; Wang X; Liu J; Ma Y; Wang X; Xu L
J Chromatogr A; 2021 Apr; 1642():462000. PubMed ID: 33684874
[TBL] [Abstract][Full Text] [Related]
9. Growth Differentiation Factor 15 Is a Novel Diagnostic Biomarker of Mitochondrial Diseases.
Ji X; Zhao L; Ji K; Zhao Y; Li W; Zhang R; Hou Y; Lu J; Yan C
Mol Neurobiol; 2017 Dec; 54(10):8110-8116. PubMed ID: 27889897
[TBL] [Abstract][Full Text] [Related]
10. Associations of FGF21 and GDF15 with mitochondrial dysfunction in children living with perinatally-acquired HIV: A cross-sectional evaluation of pediatric AIDS clinical trials group 219/219C.
Gojanovich GS; Jacobson DL; Broadwell C; Karalius B; Kirmse B; Geffner ME; Jao J; Van Dyke RB; McFarland EJ; Silio M; Crain M; Gerschenson M;
PLoS One; 2021; 16(12):e0261563. PubMed ID: 34972147
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease.
Lehtonen JM; Auranen M; Darin N; Sofou K; Bindoff L; Hikmat O; Uusimaa J; Vieira P; Tulinius M; Lönnqvist T; de Coo IF; Suomalainen A; Isohanni P
J Inherit Metab Dis; 2021 Mar; 44(2):469-480. PubMed ID: 32857451
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 21 and grow differentiation factor 15 are sensitive biomarkers of mitochondrial diseases due to mitochondrial transfer-RNA mutations and mitochondrial DNA deletions.
Formichi P; Cardone N; Taglia I; Cardaioli E; Salvatore S; Gerfo AL; Simoncini C; Montano V; Siciliano G; Mancuso M; Malandrini A; Federico A; Dotti MT
Neurol Sci; 2020 Dec; 41(12):3653-3662. PubMed ID: 32504279
[TBL] [Abstract][Full Text] [Related]
13. Determination of serum lipoprotein lipase using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer.
Machida T; Miyashita K; Sone T; Tanaka S; Nakajima K; Saito M; Stanhope K; Havel P; Sumino H; Murakami M
Clin Chim Acta; 2015 Mar; 442():130-5. PubMed ID: 25632836
[TBL] [Abstract][Full Text] [Related]
14. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
15. FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.
Lehtonen JM; Forsström S; Bottani E; Viscomi C; Baris OR; Isoniemi H; Höckerstedt K; Österlund P; Hurme M; Jylhävä J; Leppä S; Markkula R; Heliö T; Mombelli G; Uusimaa J; Laaksonen R; Laaksovirta H; Auranen M; Zeviani M; Smeitink J; Wiesner RJ; Nakada K; Isohanni P; Suomalainen A
Neurology; 2016 Nov; 87(22):2290-2299. PubMed ID: 27794108
[TBL] [Abstract][Full Text] [Related]
16. Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes.
Murakami T; Ueba Y; Shinoto Y; Koga Y; Kaneda D; Hatoko T; Kato T; Yonemitsu S; Muro S; Oki S
Tohoku J Exp Med; 2016 Jun; 239(2):89-94. PubMed ID: 27212224
[TBL] [Abstract][Full Text] [Related]
17. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study.
Suomalainen A; Elo JM; Pietiläinen KH; Hakonen AH; Sevastianova K; Korpela M; Isohanni P; Marjavaara SK; Tyni T; Kiuru-Enari S; Pihko H; Darin N; Õunap K; Kluijtmans LA; Paetau A; Buzkova J; Bindoff LA; Annunen-Rasila J; Uusimaa J; Rissanen A; Yki-Järvinen H; Hirano M; Tulinius M; Smeitink J; Tyynismaa H
Lancet Neurol; 2011 Sep; 10(9):806-18. PubMed ID: 21820356
[TBL] [Abstract][Full Text] [Related]
18. Serum Growth Differentiation Factor 15 in Parkinson Disease.
Yao X; Wang D; Zhang L; Wang L; Zhao Z; Chen S; Wang X; Yue T; Liu Y
Neurodegener Dis; 2017; 17(6):251-260. PubMed ID: 28787735
[TBL] [Abstract][Full Text] [Related]
19. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP
J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769
[TBL] [Abstract][Full Text] [Related]
20. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer.
Li C; Wang X; Casal I; Wang J; Li P; Zhang W; Xu E; Lai M; Zhang H
J Cell Mol Med; 2016 Aug; 20(8):1420-6. PubMed ID: 26990020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
